Article

Mmarketwatch.com on 2023-07-17 16:16

Eli Lilly's Alzheimer’s treatment shows promise in early stages of disease — but safety concerns remain4 min read

Drugmaker has completed its FDA submission for approval of donanemab, with regulatory action expected by the end of this year

Wall Street

Mark Mintun

Related news

Eli Lilly's Alzheimer's Drug Shows Promise in Small Trial The New York Times
GAlzheimer’s Disease Diagnostic Market Impact and Recovery Analysis| Eli Lilly, TauRx, Alector galleonnews.com
Eli Lilly's COVID treatment gets emergency use authorization israelnationalnews.com
MEli Lilly's stock rallies after BMO raises rating, price target marketwatch.com
Lilly presents trial data on Alzheimer’s drug showing promise Merced Sun-Star
Minnesota , Rochester , Las Vegas , Wall Street
MEli Lilly's Emgality gets FDA approval for episodic cluster headaches marketwatch.com
MEli Lilly's stock gains after earnings, revenue rise above expectations marketwatch.com
MEli Lilly's cluster-headache treatment passes phase 3 test marketwatch.com
IEli Lilly Q2 results: its Alzheimer’s drug could be ‘the biggest drug in history’invezz.com
Wall Street , China , North America
Eli Lilly's Alzheimer's drug slows progression, carries risk of brain swelling, bleeding, study says CBC
Toronto , San Francisco , Canada , Amsterdam , Japan
The Signs and Stages of Alzheimer’s Disease trumbulltimes.com
White Plains
MNew pain drug from Pfizer and Eli Lilly shows promise as opioid alternative marketwatch.com
New York , Wall Street , Americas
Eli Lilly's drug is latest failure in search for treatment to slow Alzheimer's LA Times
Upland , Compton , New York , Wall Street , United States
FAstraZeneca and Eli Lilly scrap Alzheimer’s trial ft.com
FEli Lilly raises Alzheimer’s drug hopes ft.com
Washington
MEli Lilly's Elanco sets IPO terms to raise up to $1.45 billion before options marketwatch.com
Eli Lilly's next CEO could carry first Alzheimer's treatment across the finish line IndyStar
BEli Lilly's Earnings Top Forecasts and 2022 Outlook Is Maintained1 min read barrons.com
MEli Lilly's Taltz meets primary endpoint in late-state trial for AS treatment marketwatch.com